Lurasidone as a potential therapy for bipolar disorder

Young Sup Woo, Hee Ryung Wang, Won-Myong Bahk Department of Psychiatry, Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, Korea Abstract: Lurasidone is a benzisothiazol derivative and an atypical antipsychotic approved by the US Food and Drug Administration for the acute t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Woo YS, Wang HR, Bahk WM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bc7a54e3b15f4ed8993d5ea38d81b303
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc7a54e3b15f4ed8993d5ea38d81b303
record_format	dspace
spelling	oai:doaj.org-article:bc7a54e3b15f4ed8993d5ea38d81b3032021-12-02T01:31:59ZLurasidone as a potential therapy for bipolar disorder1176-63281178-2021https://doaj.org/article/bc7a54e3b15f4ed8993d5ea38d81b3032013-10-01T00:00:00Zhttp://www.dovepress.com/lurasidone-as-a-potential-therapy-for-bipolar-disorder-a14612https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Young Sup Woo, Hee Ryung Wang, Won-Myong Bahk Department of Psychiatry, Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, Korea Abstract: Lurasidone is a benzisothiazol derivative and an atypical antipsychotic approved by the US Food and Drug Administration for the acute treatment of adults with schizophrenia (October 2010) and bipolar 1 depression (June 2013). Lurasidone has a strong antagonistic property at the D2, serotonin (5-HT)2A, and 5-HT7 receptors, and partial agonistic property at the 5-HT1A receptor. Lurasidone also has lower binding affinity for the α2C and 5-HT2C receptor. Lurasidone is rapidly absorbed (time to maximum plasma concentration: 1–3 hours), metabolized mainly by CYP3A4 and eliminated by hepatic metabolism. In two large, well-designed, 6-week trials in adult patients with bipolar 1 depression, lurasidone monotherapy and adjunctive therapy with mood stabilizers were significantly more effective than placebo at improving depressive symptoms assessed using the Montgomery–Åsberg Depression Rating Scale total score. In both trials, lurasidone also reduced the Clinical Global Impression–Bipolar Severity depression score to a greater extent than placebo. In these two trials, discontinuation rates due to adverse events in the lurasidone group were small (<7%) and were not different from those of the placebo group. The most common adverse events in the lurasidone group were headache, nausea, somnolence, and akathisia. The changes in lipid profiles, weight, and parameters of glycemic control were minimal, and these findings were in line with those observed in schizophrenia trials. Further active comparator trials and long-term tolerability and safety data in bipolar patients are required. Lurasidone may be an option for the management of depressive symptoms in patients with bipolar 1 disorder, and it may be considered as a treatment alternative for patients who are at high risk for metabolic abnormalities. Keywords: lurasidone, bipolar disorder, acute depression, metabolicWoo YSWang HRBahk WMDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1521-1529 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Woo YS Wang HR Bahk WM Lurasidone as a potential therapy for bipolar disorder
description	Young Sup Woo, Hee Ryung Wang, Won-Myong Bahk Department of Psychiatry, Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, Korea Abstract: Lurasidone is a benzisothiazol derivative and an atypical antipsychotic approved by the US Food and Drug Administration for the acute treatment of adults with schizophrenia (October 2010) and bipolar 1 depression (June 2013). Lurasidone has a strong antagonistic property at the D2, serotonin (5-HT)2A, and 5-HT7 receptors, and partial agonistic property at the 5-HT1A receptor. Lurasidone also has lower binding affinity for the α2C and 5-HT2C receptor. Lurasidone is rapidly absorbed (time to maximum plasma concentration: 1–3 hours), metabolized mainly by CYP3A4 and eliminated by hepatic metabolism. In two large, well-designed, 6-week trials in adult patients with bipolar 1 depression, lurasidone monotherapy and adjunctive therapy with mood stabilizers were significantly more effective than placebo at improving depressive symptoms assessed using the Montgomery–Åsberg Depression Rating Scale total score. In both trials, lurasidone also reduced the Clinical Global Impression–Bipolar Severity depression score to a greater extent than placebo. In these two trials, discontinuation rates due to adverse events in the lurasidone group were small (<7%) and were not different from those of the placebo group. The most common adverse events in the lurasidone group were headache, nausea, somnolence, and akathisia. The changes in lipid profiles, weight, and parameters of glycemic control were minimal, and these findings were in line with those observed in schizophrenia trials. Further active comparator trials and long-term tolerability and safety data in bipolar patients are required. Lurasidone may be an option for the management of depressive symptoms in patients with bipolar 1 disorder, and it may be considered as a treatment alternative for patients who are at high risk for metabolic abnormalities. Keywords: lurasidone, bipolar disorder, acute depression, metabolic
format	article
author	Woo YS Wang HR Bahk WM
author_facet	Woo YS Wang HR Bahk WM
author_sort	Woo YS
title	Lurasidone as a potential therapy for bipolar disorder
title_short	Lurasidone as a potential therapy for bipolar disorder
title_full	Lurasidone as a potential therapy for bipolar disorder
title_fullStr	Lurasidone as a potential therapy for bipolar disorder
title_full_unstemmed	Lurasidone as a potential therapy for bipolar disorder
title_sort	lurasidone as a potential therapy for bipolar disorder
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/bc7a54e3b15f4ed8993d5ea38d81b303
work_keys_str_mv	AT wooys lurasidoneasapotentialtherapyforbipolardisorder AT wanghr lurasidoneasapotentialtherapyforbipolardisorder AT bahkwm lurasidoneasapotentialtherapyforbipolardisorder
_version_	1718403035721367552

Lurasidone as a potential therapy for bipolar disorder

Ejemplares similares